The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:
X-A-Y-L-R  (I)
which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The present disclosure relates to a lithium secondary battery including: a non-aqueous electrolyte including a lithium salt, an organic solvent, a first additive represented by Chemical Formula 1 and a second additive represented by Chemical Formula 2; a positive electrode including a positive electrode active material including a lithium composite transition metal oxide having a nickel content of 70 mol % or more among a total transition metal content; a negative electrode including an negative electrode active material; and a separator interposed between the positive electrode and the negative electrode.

The present disclosure relates to a lithium secondary battery including: a non-aqueous electrolyte including a lithium salt, an organic solvent, a first additive represented by Chemical Formula 1 and a second additive represented by Chemical Formula 2; a positive electrode including a positive electrode active material including a lithium composite transition metal oxide having a nickel content of 70 mol % or more among a total transition metal content; a negative electrode including an negative electrode active material; and a separator interposed between the positive electrode and the negative electrode.

An ionic liquid comprising: a cation (or conjugate acid), wherein the cation (or conjugate acid) is represented by General Formula (A) below or General Formula (B) below or General Formula (C) or General Formula (D) below or General Formula (E) below: ##STR00001## wherein R.sub.1 represents CH.sub.2CH.sub.2(CF.sub.2).sub.nCF.sub.3, where n is an integer ranging from 0 to 7, or an alkyl chain CH.sub.3, or CH.sub.2OH, or CH.sub.2CH.sub.2OH; R.sub.2 represents CH.sub.2CH.sub.2(CF.sub.2).sub.nCF.sub.3, where n is an integer ranging from 0 to 7, or a hydrogen atom H, or CH.sub.2OH, or CH.sub.2CH.sub.2OH; and R.sub.3 represents CH.sub.2CH.sub.2(CF.sub.2).sub.nCF.sub.3, where n is an integer ranging from 0 to 7.

An ionic liquid comprising: a cation (or conjugate acid), wherein the cation (or conjugate acid) is represented by General Formula (A) below or General Formula (B) below or General Formula (C) or General Formula (D) below or General Formula (E) below: ##STR00001## wherein R.sub.1 represents CH.sub.2CH.sub.2(CF.sub.2).sub.nCF.sub.3, where n is an integer ranging from 0 to 7, or an alkyl chain CH.sub.3, or CH.sub.2OH, or CH.sub.2CH.sub.2OH; R.sub.2 represents CH.sub.2CH.sub.2(CF.sub.2).sub.nCF.sub.3, where n is an integer ranging from 0 to 7, or a hydrogen atom H, or CH.sub.2OH, or CH.sub.2CH.sub.2OH; and R.sub.3 represents CH.sub.2CH.sub.2(CF.sub.2).sub.nCF.sub.3, where n is an integer ranging from 0 to 7.

The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI and formula XII and, the methods for the treatment of oral infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral infectious diseases.

The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI and formula XII and, the methods for the treatment of oral infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral infectious diseases.

The invention relates to an acidic aqueous composition for electrolytic copper plating, the composition comprising (i) copper (II) ions, (ii) one or more than one suppressor consisting of or comprising one single N-heteroaromatic mono-ring, said mono-ring comprising at least two ring nitrogen atoms and more than one substituent covalently connected to one of said ring nitrogen atoms and/or a ring carbon atom, wherein said substituent independently is or comprises one or more than one linear or branched polyalkylene glycol moiety, and/or one or more than one linear or branched polyalkylene glycol block polyalkylene glycol, or random polyalkylene glycol moiety, with the proviso that if said suppressor comprises a OH group, then it is a terminal OH group of said polyalkylene glycol moiety, polyalkylene glycol block polyalkylene glycol, and random polyalkylene glycol moiety, respectively, and said suppressor does not comprise NH2 groups, halogen atoms, and sulfur atoms;
a method of electrolytic copper plating using the acidic aqueous composition; and specific suppressors as defined above.

The invention relates to an acidic aqueous composition for electrolytic copper plating, the composition comprising (i) copper (II) ions, (ii) one or more than one suppressor consisting of or comprising one single N-heteroaromatic mono-ring, said mono-ring comprising at least two ring nitrogen atoms and more than one substituent covalently connected to one of said ring nitrogen atoms and/or a ring carbon atom, wherein said substituent independently is or comprises one or more than one linear or branched polyalkylene glycol moiety, and/or one or more than one linear or branched polyalkylene glycol block polyalkylene glycol, or random polyalkylene glycol moiety, with the proviso that if said suppressor comprises a OH group, then it is a terminal OH group of said polyalkylene glycol moiety, polyalkylene glycol block polyalkylene glycol, and random polyalkylene glycol moiety, respectively, and said suppressor does not comprise NH2 groups, halogen atoms, and sulfur atoms;
a method of electrolytic copper plating using the acidic aqueous composition; and specific suppressors as defined above.

Disclosed herein, inter alia, are inhibitors of alpha 2 beta 1 integrin and methods of using the same.